Microarray analysis was used to examine effects of repeated postnatal exposure to chlorpyrifos oxon (CPO) on gene expression in the cerebellum of genetically modified mice. The high-density lipoprotein-associated enzyme paraoxonase 1 (PON1) plays a significant role in the detoxication of CPO, which is present in exposures and generated from chlorpyrifos (CPF) in vivo following exposure. Two factors are important in modulating toxicity of CPO, the Q192R PON1 polymorphism and PON1 plasma level, which is low at birth and increases throughout postnatal development. Mice used in these studies included wild type (PON1 1/1 ), PON1 knockout (PON1 2/2 ), and two transgenic lines (tgHuPON1 Q192 , tgHuPON1 R192 ) expressing either human PON1 Q192 or PON1 R192 on the PON1 2/2 background. PON1 R192 hydrolyzes CPO more efficiently than PON1 Q192 . All four genotypes exposed to CPO (0.35 or 0.50 mg/kg/day) daily from postnatal day (PND) 4 to PND 21 showed significant differences in gene expression on PND 22 compared with controls. Pathway analysis and Gene Set Analysis revealed multiple pathways and gene sets significantly affected by CPO exposure, including genes involved in mitochondrial dysfunction, oxidative stress, neurotransmission, and nervous system development. Comparison between genotypes revealed specific genes, gene sets, and pathways differentially affected between tgHuPON1 Q192 and tgHu-PON1 R192 mice and between PON1 2/2 and PON1 1/1 mice following CPO exposure. Repeated CPO exposure also resulted in a dose-related decrease in brain acetylcholinesterase activity during postnatal development in PON1 2/2 and tgHuPON1 Q192 mice but not in PON1 1/1 or tgHuPON1 R192 mice. These findings indicate that PON1 status plays a critical role in modulating the effects of neonatal CPO exposure in the developing brain.
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Key Words: chlorpyrifos; chlorpyrifos oxon; paraoxonase; organophosphorus insecticides; microarrays; neurotoxicity.
Despite restrictions imposed on residential use, the organophosphorus (OP) insecticide chlorpyrifos (CPF) is still widely used (Heudorf et al., 2006) . CPF undergoes oxidative desulfuration in the liver to form CPF oxon (CPO), which inhibits serine active-site enzymes, including acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and carboxylesterase (CES) (Chambers et al., 1990; Shenouda et al., 2009) . The oxon form itself is present in most, if not all exposures, representing 2% to more than 17% of OP residues (Cal-EPA, 1998; Vidal et al., 1998; Yuknavage et al., 1997) , with CPO residues in green beans and tomatoes reported to be as high as 0.14-0.21 mg/kg (Vidal et al., 1998) . Despite the presence of CPO in exposures, safety studies for CPF have been carried out only with highly pure parent compound (Nolan et al., 1984) . CPO is bound stoichiometrically by B-esterases, including CES (Chambers et al., 1990) ; however, it is efficiently hydrolyzed catalytically by the plasma enzyme, paraoxonase 1 (PON1) (Furlong, 2008) .
The PON1 Q192R polymorphism affects the catalytic efficiency of hydrolysis of some substrates, including CPO (Furlong, 2008) , with significant consequences in vivo. PON1 knockout (PON1 À/À ) mice are dramatically more sensitive than wild-type (PON1 þ/þ ) mice to the toxicity of CPO and diazoxon (DZO) (Furlong, 2008; Li et al., 2000; Shih et al., 1998) . Injection of rodents with purified human PON1 (Furlong, 2008) or engineered recombinant PON1 (Stevens et al., 2008) provided protection against OP toxicity. Of the purified human PON1 alloforms, PON1 R192 provided greater protection than human PON1 Q192 against exposures to CPF and CPO (Li et al., 2000) . PON1 Q192 and PON1 R192 provided equivalent protection against DZO exposure (Furlong, 2008; Li et al., 2000) . Humanized transgenic mice expressing tgHu-PON1 Q192 in the absence of mouse PON1 were more sensitive to CPF and CPO than mice expressing tgHuPON1 R192 (Cole et al., 2003 (Cole et al., , 2005 and were also more sensitive to the interactive toxicity of mixtures of OP compounds that included CPO (Jansen et al., 2009) .
PON1 levels vary by at least 14-fold among adults and 26-fold among infants (Furlong et al., 2006 ). An individual's ''PON1 status,'' which encompasses both their PON1 Q192R functional genotype and plasma PON1 level, can be determined with high-throughput microtiter-plate assays (Richter and Furlong, 1999; Richter et al., 2008) . PON1 levels are 3-to 4-fold lower in children than in adults (Furlong et al., 2006) and do not reach adult levels until 6 months to 7 years of age (Cole et al., 2003; Huen et al., 2009) . Children face additional risk due to their closer proximity to the multiple pathways of aggregate exposure, including oral ingestion, inhalation, and dermal exposure to OPs in food, air, and dust (Fenske et al., 2005) .
In a study of Washington State pesticide handlers using CPF within the previous 30 days, both the presence of PON1 Q192 and low plasma PON1 level were significantly associated with inhibition of BChE, a sensitive biomarker of OP exposure (Hofmann et al., 2009) . South African fruit-farm workers carrying the PON1 Q192 allele were nearly three times as likely as PON1 R192 homozygotes to report multiple symptoms of OP toxicity (Lee et al., 2003) .
Whereas OP compounds originally were thought to act via the common mechanism of AChE inhibition, studies over the past decade have identified additional mechanisms of toxicity (Jameson et al., 2007; Pope, 1999; Schuh et al., 2002) . Exposure of neonatal rats to subtoxic doses of CPF caused decreased cell density in the cerebellum and other brain regions (Whitney et al., 1995) . Gestational exposure of mice to CPF by Moreira et al. (2010) identified multiple dose-dependent effects on gene expression, at least some of which were unrelated to AChE inhibition. Chronic CPF exposure also can cause OPinduced delayed neuropathy (Lotti et al., 1986) . In primary human astrocytes (Mense et al., 2006) , PC12 cells (Slotkin and Seidler, 2009) , adult rats (Stapleton and Chan, 2009) , and neonatal rats , CPF altered the expression of multiple genes involved in nervous system development and function. Exposure to CPF doses as low as 1.5 mg/kg caused reduced expression of nerve growth factor, reelin, and myelin-associated glycoprotein (Betancourt et al., 2006) . CPF exposure affected neuronal replication and differentiation, synapse function, and behavior, with toxicity extending fairly late into the period of brain development (Aldridge et al., 2005) .
In contrast to CPF, studies on CPO effects have been sparse, despite its prevalence in the environment (Cal-EPA, 1998; Vidal et al., 1998; Yuknavage et al., 1997) and its dramatically higher toxicity (Huff et al., 1994; Cole et al., 2005) . CPO binds to muscarinic receptors (Huff et al., 1994) and inhibits phosphorylation and internalization of muscarinic M2 receptors in transfected CHO cells (Udarbe Zamora et al., 2008) . In human sperm, CPO and other oxons produced more extensive chromatin alteration and DNA damage than did the parent phosphorothioates . Pesticide effects on semen quality and DNA integrity are modulated by the PON1 Q192R polymorphism (Perez-Herrera et al., 2008) .
Previously, Whitney et al. (1995) demonstrated effects of subtoxic doses of CPF on cell density in the cerebellum. To gain insight into the mechanisms of neurotoxicity of CPO in this region and to ascertain the importance of the PON1 Q192R polymorphism for protecting against developmental toxicity of CPO, we used whole-genome microarrays to measure gene expression changes associated with repeated CPO exposure of developing (PND 4-21) PON1 À/À , tgHuPON1 Q192 transgenic, tgHuPON1 R192 transgenic, and PON1 þ/þ mice.
MATERIALS AND METHODS
Animals. PON1 knockout (PON1 À/À ) mice (Shih et al., 1998) and mice expressing either the human PON1 R192 or PON1 Q192 transgene (tgHuPON1 R192 or tgHuPON1 Q192 ) in place of endogenous mouse PON1 (Cole et al., 2003 (Cole et al., , 2005 were provided by Drs Diana M. Shih, Aaron Tward, and Aldons J. Lusis (University of California, Los Angeles (UCLA), Los Angeles, CA). Mice with at least one copy of the transgene were crossed with same genotype animals to produce both PON1 À/À mice and transgenic mice (tgHuPON1 R192 or tgHuPON1 Q192 ) in the same litter. Wild-type (PON1 þ/þ ) mice were bred from the same congenic B6.129 strain background. Presence of PON1 Q192 or PON1 R192 enzyme activity in heparinized saphenous-vein plasma was detected by measuring the rate of hydrolysis of either the alloform-neutral substrate, phenyl acetate (Cole et al., 2003 (Cole et al., , 2005 , or diazoxon, which is alloform-neutral at 0.5M NaCl (Richter and Furlong, 1999) and has no background activity in PON1 À/À mice (Cole et al., 2003; Stevens et al., 2008) . PCR-based genotyping was used to determine the presence of the transgenes. Arylesterase (AREase) and diazoxonase (DZOase) assays were carried out in a microtiter plate reader (SpectraMax Plus, Molecular Devices), using 0.5 ll (AREase) and 1.25 ll (DZOase) of plasma per well. Only the initial linear rates of hydrolysis were used for calculations. Mice were housed in specific pathogen free (SPF) or modified SPF facilities with a 12-h dark/light cycle and unlimited access to food and water. The animal use protocols used were approved by the Institutional Animal Care and Use Committee at the University of Washington. All animal experiments were carried out in accordance with the National Research Council Guide for the Care and Use of Laboratory Animals, as adopted by the National Institutes of Health.
Chemicals. CPO (CAS 5598-15-2; 98% purity) was purchased from Chem Service (West Chester, PA). Acetylthiocholine, 5,5#-dithio-bis-nitrobenzoic acid (DTNB), p-nitrophenyl valerate, and phenyl acetate were from SigmaAldrich (St Louis, MO). All other analytical grade chemicals were obtained from commercially available sources.
Exposure of mice to CPO. Timed matings of the humanized transgenic mice (tgHuPON1 Q192 3 tgHuPON1 Q192 ; tgHuPON1 R192 3 tgHuPON1 R192 ) were used to generate litters comprised of both PON1 À/À and tgHuPON1 R192 or tgHuPON1 Q192 mice. PON1 þ/þ litters, and in some cases PON1 À/À litters, were generated by timed mating of homozygous (PON1 À/À or PON1 þ/þ ) males and females. On postnatal day (PND) 4, litters were culled to six mice (three males and three females, when possible). Mice were injected sc (1 ll/g bodyweight) with CPO (0, 0.15, 0.18, 0.25, 0.35, or 0 .50 mg/kg/day) daily from PND 4 to PND 21. A 1 mg/ml stock solution of CPO (Chem Service, 98% purity) dissolved in dimethyl sulfoxide (DMSO) was used to make serial dilutions for injections. Control mice received vehicle (DMSO) alone. All mice within a litter received the same dose of CPO, and the litter was used as the unit of dosage; i.e., only one mouse was used per litter for each endpoint. The experiments reported here were part of a larger study that also examined other endpoints of toxicity (Cole, Fisher, Walter, Burbacher, Costa, and Furlong, in preparation per litter for measurement of gene expression. One male and one female mice were used per litter for measurement of brain acetylcholinesterase (AChE) activity. The remaining mice were used for assessment of histopathology or neurobehavior, the results of which are not reported here (Cole, Fisher, Walter, Burbacher, Costa, Furlong, in preparation) . Bodyweights of all mice were measured daily just prior to dosing, and the dates of appearance of developmental landmarks (eye opening, pinna detachment, hair growth) were recorded. At weaning (PND 22), mice to be used for gene expression assessment (n ¼ 6 male mice for each genotype and treatment group; one mouse from each litter) were euthanized by CO 2 asphyxiation, 24 h after the last injection. Upon dissection, the brains were bisected sagittally, and cerebella were separated and immersed in 10 volumes of RNAlater solution (Ambion, Austin, TX) for stabilization of RNA prior to extraction. For AChE measurement, dissected brains were immediately frozen on dry ice and stored at À80°C until analysis. Statistical differences in bodyweight among treatment groups were determined by calculating the mean bodyweights of males and females for each litter and using Student's t-test to test for statistical significance of the differences between means.
Brain AChE assays. Brains frozen and stored at À80°C were thawed and homogenized for 30 s in 0.1M sodium phosphate, pH 8.0 using a Polytron homogenizer (Brinkmann Instruments, Westbury, NY). Brain AChE activity was measured as described (Cole et al., 2005; Jansen et al., 2009) , using a SpectraMax Plus microtiter plate reader (Molecular Devices). The initial rates of 5-thio-2-nitrobenzoate formed during the assay (mOD/min) were pathlength-corrected and converted to U/g of wet tissue using an extinction coefficient of 13.6mM
À1 cm
À1
. AChE activity is expressed as U/g of wet tissue (U ¼ lmol of acetylthiocholine hydrolyzed per minute). Statistical differences in brain AChE activity between treatment groups and genotypes were determined using Student's t-test.
RNA extraction, labeling, and microarray hybridization. The bisected cerebella in RNAlater were incubated for at least 12 h at 4°C, then stored at À20°C. Total RNA was isolated using TRIZOL Reagent and the QIAamp Tissue Kit from QIAGEN Inc., according to the manufacturer's established protocols. The quality of the total RNA was evaluated using an Agilent 2100 Bioanalyzer. Only samples with high integrity (integrity number > 8), adequate RNA quantity, and an A 260 :A 280 ratio of 1.8-2.1 were used for further analyses. Sixty RNA samples (n ¼ 5-6 from all but two of the experimental groups) met these requirements. The exceptions were PON þ/þ and PON1 À/À mice exposed to 0.50 mg/kg/day CPO, for which there were three and four samples, respectively. A NanoDrop spectrophotometer (Thermo Scientific, Wilmington, DE) was used to determine RNA concentrations based on A 260 measurements.
Affymetrix GeneChip whole transcript sense target labeling and hybridization. RNA samples isolated from individual cerebella were labeled and hybridized individually to Affymetrix Mouse Genome ST 1.0 microarrays. Processing of the RNA samples was carried out according to the Affymetrix GeneChip Whole Transcript Sense Target labeling protocol (for details, see http://www.affymetrix.com/index.affx). Briefly, double-stranded cDNA was synthesized with random hexamers tagged with a T7 promoter sequence. The double-stranded cDNA was subsequently used as a template and amplified by T7 RNA polymerase producing many copies of antisense cRNA. In the second cycle of cDNA synthesis, random hexamers were used to prime reverse transcription of the cRNA from the first cycle to produce single-stranded DNA in the sense orientation. In order to reproducibly fragment the single-stranded DNA and improve the robustness of the assay, a novel approach was utilized where dUTP was incorporated in the DNA during the second-cycle first-strand reverse transcription reaction. This single-stranded DNA sample was then treated with a combination of uracil DNA glycosylase (UDG) and apurinic/ apyrimidinic endonuclease 1 (APE-1) that specifically recognizes the unnatural dUTP residues and cuts the DNA strand. DNA was labeled by terminal deoxynucleotidyl transferase (TdT) with the Affymetrix proprietary DNA Labeling Reagent covalently linked to biotin. The biotin-labeled DNA fragments were hybridized to the array, washed, and stained with streptavidin and a fluorescent anti-streptavidin antibody. Following an additional wash step, the arrays were scanned with an Affymetrix GeneChip 3000 scanner. Image generation and feature extraction was performed using Affymetrix AGCC Software. For MIAME compliance (Brazma et al., 2001 ) raw data, final processed data, sample and array annotation, and experimental design have been submitted to the NCBI Gene Expression Omnibus (GEO) and are available at http://www.ncbi.nlm.nih.gov/geo/, accession #GSE25250.
Microarray data quality control. Several microarray data QC metrics were applied to assure high quality of the data. The first QC step was a visual inspection of the scanned image to check for fluorescent signal artifacts. In addition, the background signals were assessed and required to be below the manufacturer's recommended threshold. The distribution of the fluorescent signals of arrays within a given experiment was assessed by box plots and outliers were identified. In addition, normalized un-scaled standard errors were calculated for each array and outliers were identified. Only data that passed all QC steps were included in the analyses.
Microarray data analysis: individual gene analysis. Raw microarray data were processed and analyzed with Bioconductor (Gentleman et al., 2004) and normalized using the Robust Multi-Array method from the Bioconductor Affy package. Using the normalized data, genes with significant evidence for differential expression were identified with the limma package (Smyth, 2004) in Bioconductor. p Values were calculated with a modified t-test in conjunction with an empirical Bayes method to moderate the standard errors of the estimated log-fold changes. p Values were adjusted for multiplicity with Bioconductor's qvalue package (Storey and Tibshirani, 2003) , which allows for selecting genes with statistically different levels of expression while controlling the estimated false discovery rate.
Ingenuity Pathway Analysis. Functional and network analyses of statistically significant gene expression changes were performed using Ingenuity Pathways analysis (IPA) (Ingenuity Systems, Redwood City, CA). Analysis considered all genes from the data set that met the 1.5-fold (p < 0.05) change cutoff and that were associated with biological functions and canonical pathways in the Ingenuity Pathways Knowledge Base. For all analyses, Fisher's exact test was used to determine the probability that each biological function assigned to the genes within each data set was not due to chance alone.
Gene Set Analysis. Gene set analysis (GSA) was used to investigate categories of genes where the constituent genes showed coordinated changes in expression for the various experimental comparisons. GSA is a recently established category/pathway analytical method and GSA software is freely available as R code (Efron and Tibshiran, 2007) . GSA considers all genes in the experiment and allows for the identification of gene sets/pathways with genes that show modest but concordant changes in gene expression. Five databases of gene sets were used for GSA; three from the Gene Ontology (Camon et al., 2004) (biological process [BP] , molecular function [MF] , and cellular component [CC] ) and five from the Broad Institute's Molecular Signature Database (http:// www.broad.mit.edu/gsea/msigdb/msigdb_index.html) (Subramanian et al., 2005) .
Quantitative real-time PCR (qRT-PCR) analysis. Reverse transcription (RT) was performed according to the Applied Biosystems Inc. (Foster City, CA) protocol using total RNA and the SuperScript II First-Strand Synthesis System (Invitrogen, Carlsbad, CA). The PCR primers and the dual-labeled probes for the specific genes of interest were contained in the Applied Biosystems (AB) inventoried TaqMan Gene Expression Assays mix and processed according to AB's protocol. For these gene expression measurements, 2 ll of cDNA were included in a PCR reaction (20 ll final volume) that also contained the appropriate forward and reverse primers, probe, and TaqMan Gene Expression Master Mix (Applied Biosystems Inc.).
Amplification and detection of PCR amplicons were performed with the ABI PRISM 7900 system (Applied Biosystems Inc.) with the following PCR profile: 1 cycle of 95°C for 10 min, 40 cycles of 95°C for 30 s and 62°C for 1 min. The 18S rRNA amplification plots derived from serial dilutions of an established reference sample were used to create a linear regression formula and calculate expression levels. The expression level of the house keeping gene, fibroblast growth factor intracellular-binding protein (Fibp), was utilized as an internal control for normalizing the data. Fibp expression was not different among genotypes and did not change following exposure to CPO.
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RESULTS
There were no overt toxic effects associated with repeated postnatal exposure to CPO, and mice developed apparently normally, with no delay in the appearance of developmental landmarks. Repeated exposure of male (but not female) PON1 À/À mice to 0.50 mg/kg/day CPO was associated with reduced bodyweight on PND 21 (8.13 ± 0.33 g vs 9.78 ± 0.50 g; p ¼ 0.027, Student's t-test). Bodyweights of mice in the other treatment groups and genotypes were not significantly affected by exposure to 0.35 mg/kg/day CPO or 0.50 mg/kg/day CPO, although there was a nonsignificant tendency toward reduced bodyweight in male PON1 À/À mice exposed to 0.35 mg/kg/day CPO (9.46 ± 0.64 g vs 9.78 ± 0.50 g; p ¼ 0.695, Student's t-test). At higher doses (! 0.625 mg/kg/day), repeated exposure of PON1 À/À or tgHu-PON1 Q192 mice to CPO was associated with lethality after 3-5 days.
Inhibition of Brain AChE
Daily exposure to CPO from PND 4 to 21 resulted in depression of AChE activity in the brains of PON1 À/À mice and tgHuPON1 Q192 transgenic mice, but not PON1 þ/þ mice or tgHuPON1 R192 transgenic mice, on PND 22 (Fig. 1) . First, to address the importance of PON1 status for protecting against CPO exposures during early neonatal development, a dose response of CPO on brain AChE inhibition was measured in PON1 þ/þ mice and PON1 À/À mice on PND 4, 2 h after CPO exposure (Fig. 1A) . The EC 50 of CPO for acute inhibition of brain AChE on PND 4 was 0.63 mg/kg in PON1 þ/þ mice and 0.23 mg/kg in PON1 À/À mice (Fig. 1A) , indicating a greater than 2.5-fold difference in sensitivity of PON1 À/À neonates to CPO. In mice of all genotypes, brain AChE was low (~2 units/g wet weight) on PND 4 and increased throughout postnatal development, reaching levels of 6-8 units/g by PND 21 (Fig. 1B , data not shown for all genotypes). Daily exposure from PND 4 to 21 was associated with depression of brain AChE (Figs. 1B and 1C) , and this effect was modulated by PON1 genotype (Fig. 1C) . Exposure of PON1 À/À mice to 0.25 mg/kg CPO on PND 4, and subsequently on PND 5, resulted in 44 and 36% inhibition of brain AChE, respectively, 2 h following CPO exposure (Fig. 1B) . On PND 13, after daily exposure of PON1 À/À mice to 0.25 mg/kg/day CPO from PND 4 to 12, brain AChE was inhibited by 17-20% compared with vehicle-treated mice (Fig. 1B) but there was no additional acute inhibition of brain AChE measured 2 h after administration of the CPO dose on PND 13 (Fig. 1B) . Similarly, on PND 21, after daily exposure to 0.25 mg/kg/day CPO from PND 4 to 20, brain AChE was inhibited by 26-27% compared with vehicle-treated mice (Fig. 1B) , but there was no additional acute inhibition of brain AChE measured 2 h (Fig. 1B ) or 4 h (not shown) after administration of the CPO dose on PND 21. Brain AChE activity measured on PND 22, 24 h after the last administration of CPO, was lower in PON1 À/À mice and tgHuPON1 Q192 transgenic mice (exposed to CPO daily from PND 4 to 21) than in control mice (Fig. 1C) . Brain AChE activity decreased in a dose-dependent manner, with maximal inhibition of 41 ± 6% in PON1 À/À mice and 22 ± 5% in tgHuPON1 Q192 transgenic mice at the 0.5 mg/kg/day dose of CPO (Fig. 1C) . PON1 þ/þ mice and tgHuPON1 R192 mice were resistant to the inhibition of brain AChE (Fig. 1C) . None of these doses of CPO inhibited brain AChE acutely on PND 21 in any of the genotypes used in these experiments (Fig. 1B; data not shown for all genotypes and doses).
Gene Expression in the Cerebellum
Previously, Whitney et al. (1995) demonstrated effects of subtoxic doses of CPF on cell density in the cerebellum. To determine the effects of CPO on gene expression in this region and to assess differences in the protective capacities of the PON1 Q192 and PON1 R192 alloforms, RNA samples were isolated from individual cerebella, then labeled and hybridized individually to Affymetrix Mouse Genome ST 1.0 microarrays (tgHuPON1 Q192 and tgHuPON1 R192 mice:
. Following data normalization, mean intensity values for each genotype and treatment group were used to make multiple comparisons among all genotypes and treatment groups (Supplementary Table 1 ).
Individual Gene Analysis
Initial analyses focused on changes in expression of individual genes for comparisons of interest, using a statistical cutoff of p < 0.05 and jfold changej > 1.5. More stringent cutoff values for fold change resulted in unacceptable filtering of the more subtle effects on gene expression and in difficulties with data interpretation due to the low numbers of affected genes. Subsequent GSA that incorporated lower level effects, discussed in more detail below, allowed a more powerful statistical analysis of the CPO effects among genotypes. Supplementary Table 2 lists the transcripts for which there were significant (p < 0.05) differences in expression between PON1 þ/þ and PON1 À/À mice , or between tgHuPON1 Q192 and tgHuPON1 R192 mice, following treatment with 0.50 or 0.35 mg/kg/day CPO, or between the respective control groups (DMSO alone). Supplementary Table 2 also lists, for each of the four genotypes, the individual transcripts for which there were significant (p < 0.05) differences in expression between mice treated with 0.5 mg/kg/day CPO and mice treated with DMSO or between mice treated with 0.35 mg/kg/day CPO and mice treated with DMSO. Figure 2 shows heat maps for the 1261 transcripts that were differentially expressed (p < 0.05; jfold changej > 1.5)
, tgHuPON1 Q192 , and tgHuPON1 R192 mice with 0.35 and 0.50 mg/kg/day CPO.
COLE ET AL.
Of the 1261 transcripts (representing 4.4% of the 28,818 transcripts on the array), 758 corresponded to known genes. Unsupervised clustering indicated distinct patterns of gene expression among mice of the different genotypes, with the 0.35 and 0.50 mg/kg/day treatment groups clustering together for each of the four genotypes. PON1 À/À mice had gene expression patterns that were most dissimilar from the other genotypes (Fig. 2) . Four-way Venn diagrams of the 812 transcripts that were differentially expressed following treatment with 0.50 mg/ kg/day CPO and 622 transcripts differentially expressed following treatment with 0.35 mg/kg/day CPO indicated that there was little overlap in affected transcripts among mice of the four genotypes (Fig. 3) . Most of the significant (p < 0.05) effects on gene expression reflected less than a 1.5-fold change, probably due to the relatively low doses used in the study. Of the 732 transcripts differentially expressed between genotypes in control mice (exposed to DMSO), the highest number of differentially expressed genes were in the PON1 Table 2) . Surprisingly, PON2 expression was reduced in the PON1 À/À mice compared with PON1 þ/þ mice (14-36% lower by microarray analysis, p < 0.01), regardless of treatment. This observation was confirmed using qRT-PCR which demonstrated decreased expression of PON2 in the cerebella of PON1 À/À , tgHuPON1 Q192 , and tgHuPON1 R192 mice compared with PON1 þ/þ mice (Table 1) . PON1 gene disruption in these three lines of mice likely affected the regulatory sequences that control expression of the nearby PON2 gene. PON2 expression was not affected by CPO exposure (fold change [mean of all four genotypes] for 0.35 mg/kg/day CPO vs. DMSO, À1.017; fold change [mean of all four genotypes] for 0.50 mg/kg/day CPO vs. DMSO, þ1.073), an observation that was confirmed by qRT-PCR (Table 1) . As expected, PON1 was expressed in the cerebellum of PON1 þ/þ mice but not in PON1 À/À mice.
Ingenuity Pathway Analysis (IPA)
IPA was used to determine the functional categories of differentially expressed genes. Genes that had a p value < 0.05 and a jfold changej > 1.5 were analyzed by IPA. Figure 4 shows 
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the top six canonical pathways identified by IPA based on these gene expression changes for the comparison of PON1 þ/þ and PON1 À/À mice exposed to 0.5 mg/kg/day CPO and for tgHuPON1 Q192 mice exposed to 0.5 mg/kg/day CPO compared with vehicle control. Mitochondrial dysfunction, oxidative phosphorylation, and protein ubiquitination were the top three canonical pathways that were elevated in PON1 À/À mice exposed to 0.5 mg/kg/day CPO, as compared with PON1 þ/þ mice exposed to 0.5 mg/kg/day CPO (Fig. 4A) . Oxidative phosphorylation, mitochondrial dysfunction, and ubiquinone biosynthesis were also the top three pathways that were elevated in tgHuPON1 Q192 mice following exposure to 0.5 mg/kg/day CPO compared with the same genotype mice exposed to vehicle control (Fig. 4B) . These results are consistent with the GSA described below, which also showed increased sensitivity of PON1 À/À and tgHuPON1 Q192 mice to the effects of CPO. 
Gene Set Analysis (GSA)
The relatively low number of genes whose gene expression was altered greater than 1.5-fold was not surprising given the relatively low doses of CPO used for the study and signal dilution due to the use of the entire cerebellum. Because lowlevel exposures are likely to produce smaller effect sizes, GSA was used to further investigate the functional categories of differentially expressed genes. GSA provides the advantage of being able to test entire gene sets, rather than individual genes, for statistically significant enrichment among treatment groups. This is a particular advantage for data sets where effects on expression of individual genes may be minor, but when analyzed together as gene sets can become highly significant. For the category analysis, GSA was performed based on the three Gene Ontology hierarchies: BP, MF, and CC. In addition, five gene set collections were used from the Broad Institute (http:// www.broad.mit.edu/gsea/msigdb/index.jsp). For each of the eight gene set collections, two summary files were generated for each of the 30 contrasts, for a total of 480 summary files.
Summary files contained the Gene Set name, GSA Enrichment Score, Raw p value, False Discovery Rate, Gene Set length, and a description of the gene set. Gene set enrichment was categorized as ''positive'' or ''negative'' based on the methods of Efron and Tibshirani (2007) , which take into account the number of upregulated and downregulated genes, the degree of up-or downregulation, and the values of the individual t-statistics. While the interpretation is somewhat more complicated, the general idea is that in gene sets with positive enrichment, upregulation predominates in the comparison group (i.e., mice treated with CPO or mice of a specific genotype) compared with the control group (i.e., mice receiving vehicle control or mice of a different genotype), whereas downregulation predominates in gene sets with negative enrichment. For a more detailed explanation, see Efron and Tibshirani (2007) .
Individual reports were generated for each gene set that was significantly enriched in any comparison. These individual reports contained GSA enrichment scores for the genes in the gene set versus GSA enrichment scores for all genes, GSA enrichment Note. PON2 expression levels (adjusted quantity mean ± SE) in cerebellum, determined by qRT-PCR.
FIG. 4.
IPA: Top six canonical pathways identified by IPA based on gene expression changes (p < 0.05; jfold changej > 1.5) between A) PON1 þ/þ and PON1 À/À mice exposed to 0.5 mg/kg/day CPO (n ¼ 3-4), and B) tgHuPON1 Q192 mice exposed to 0.5 mg/kg/day CPO (n ¼ 5) and tgHuPON1 Q192 mice exposed to vehicle control (n ¼ 5).
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161 scores for genes with hyperlinks to additional information, a heat map of the signal intensities with the average of the control values used as the baseline, and a heat map of the correlation of the above signal intensities to show how well the gene set genes were correlated across the samples. Supplementary Table 3 lists the CC, BP, and MF gene sets significantly (p < 0.05) enriched for the comparisons of 0.5 mg/kg/day CPO versus DMSO and 0.35 mg/kg/day CPO versus DMSO for all four genotypes. Supplementary Table 4 lists the CC, BP, and MF gene sets for the PON1 þ/þ versus PON1 À/À and tgHuPON1 Q192 versus tgHu-PON1 R192 comparisons at 0.5 mg/kg/day CPO.
Gene Set Venn Diagrams
To facilitate analysis of the GSA data, Venn diagrams were used to determine overlapping gene sets among the treatment groups. The most useful of these comparisons were four-way Venn diagrams that compared significantly enriched gene sets (for 0.50 mg/kg/day CPO vs. vehicle control and 0.35 mg/kg/ day CPO vs. vehicle control) among mice of each of the four genotypes. Two examples are shown in Figure 5 , for gene sets in the CC and BP gene ontology categories. The results with these two categories of gene sets illustrate a finding that was also true for the other six GO and BROAD gene set categories ( Supplementary Fig. 1 ) the only significant overlap in affected gene sets was between the PON1 À/À mice and tgHuPON1 Q192 transgenic mice (Fig. 5) . This is of particular interest because these two genotypes are known to be the most sensitive to the acute toxicity associated with exposure to CPO at higher doses.
Analysis of Specific Gene Sets
There were 98 gene sets that were significantly different at p < 0.01 between PON1 þ/þ and PON1 À/À mice exposed to 0.5 mg/ kg/day CPO and an additional 60 gene sets that were significantly different at p < 0.05. There were 21 gene sets that were significantly different at p < 0.01 between tgHuPON1 Q192 and tgHuPON1 R192 mice exposed to 0.5 mg/kg/day CPO and an additional 74 gene sets that were significantly different at p < 0.05. Figure 6 shows heat maps of five selected gene sets that were significantly different (p < 0.01) between PON1 þ/þ and PON1 À/À mice exposed to 0.5 mg/kg/day CPO, and one of the gene sets that was significantly different between tgHuPON1 Q192 and tgHuPON1 R192 mice exposed to 0.5 mg/kg/day CPO. Figure  7 shows heat maps for one BP gene set (Synapse Organization; BP GO_0050808) that was significantly enriched for several different comparisons, including tgHuPON1 R192 mice versus tgHuPON1 Q192 mice exposed to 0.5 mg/kg/day CPO and PON1 þ/þ versus PON1 À/À mice exposed to 0.5 mg/kg/day CPO. Intriguingly, this gene set showed effects on the neuroligins, transmembrane proteins that span the synapse, are involved in trans-synaptic signaling, and are members of the cholinesterase family. Virtually all of the heat maps showed stronger effects, as indicated by the larger magnitude of the changes in gene expression (both upregulation and downregulation), in the
PON1
À/À mice and tgHuPON1 Q192 mice compared with the PON1 þ/þ and tgHuPON1 R192 mice (Figs. 6 and 7) .
Quantitative Real-Time PCR Confirmation Microarray data for selected genes were confirmed independently by quantitative real-time PCR (qRT-PCR) (Fig. 8) . Microarray data and qRT-PCR data indicated upregulation of ATPase, calcium transporting, plasma membrane 2 (Atp2b2), cholinergic receptor, nicotinic, beta polypeptide 4 (Chrnb4), glutamate receptor, metabotropic 2 (Grm2), neuroligin 2 (Nlgn2), and synapsin II (Syn2), and downregulation of glutathione Stransferase, alpha 4 (Gsta4), and peptidylprolyl isomerase (cyclophilin)-like 6 (Ppil6), after repeated exposure to 0.5 mg/kg/day CPO. The upregulation or downregulation of these genes was reduced in mice exposed to 0.35 mg/kg/day CPO. PON2 expression was lower in the PON1 À/À mice than in PON1 þ/þ mice, regardless of exposure (Table 1 ). Figure 9 shows dose-dependent responses of repeated CPO exposure on the expression of specific genes, measured by qRT-PCR, in the cerebella of PON1 À/À mice. There were dosedependent increases in expression of Nlgn2, Grm2, and Syn2, and a dose-dependent decrease in expression of Gsta4 (Fig. 9) .
DISCUSSION
This study showed that repeated developmental exposure to CPO is associated with alterations in gene expression and enzyme activity in the cerebellum and that PON1 status is important for modulating these effects. Whereas the levels of CPO used in these studies do not inhibit AChE when given acutely to adult animals, brain AChE activity was reduced after repeated exposure of mice from PND 4 to 21, and repeated developmental CPO exposure was associated with changes in the expression of many different genes in the cerebellum. To our knowledge, this is the first study examining the effects of repeated OP-oxon exposures on gene expression, and the first study to examine the modulation of gene expression effects by PON1 status. Previous studies have examined the effects of developmental exposure of mice, rats, or cultured cells to the parent organophosphorothioates (Mense et al., 2006; Seidler, 2007, 2009; Stapleton and Chan, 2009; Moreira et al., 2010) .
By individual gene analysis, a total of 812 transcripts were differentially expressed (p < 0.05; jfold changej > 1.5) following treatment of mice with 0.50 mg/kg/day CPO, and 622 transcripts were differentially expressed following exposure of mice to 0.35 mg/kg/day CPO. IPA identified the top canonical pathways that contained these genes. However, many of the statistically significant effects on gene expression involved changes that were below 1.5-fold, which was not surprising given the relatively low-level exposures. GSA was particularly useful in determining classes of proteins whose expression was affected by CPO exposure. Specific categories of gene sets examined included the CC, BP, and MF Gene Ontology gene sets, and the five Broad Institute Gene Set collections.
The mitochondrion was conspicuous as a cellular component for which many genes showed differential expression with treatment and among genotypes, and the mitochondrial inner membrane presequence complex (GO:0005744), mitochondrial intermembrane space protein transporter complex (GO:0042719), mitochondrial respiratory chain (GO:0005746; GO:0005747), and mitochondrial proton-transporting ATP synthase complex coupling factor F(0) (GO:0000276) were among the 15 CC positive gene sets that overlapped between the PON1 À/À and tgHuPON1 Q192 groups. ''Mitochondrial dysfunction'' and ''oxidative phosphorylation'' also were identified by IPA as the top two canonical pathways affected by exposure based on analysis of individual genes with jfold changej > 1.5 and statistical significance of p < 0.05. The involvement of oxidative stress and mitochondrial dysfunction in CPO toxicity would be consistent with other studies suggesting oxidative stress as an important Individual gene sets enriched in both PON1 À/À and tgHuPON1 Q192 mice exposed to 0.5 mg/kg/day CPO are listed below the respective Venn diagrams.
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contributor to the toxicity associated with OP exposures (Moreira et al., 2010; Seidler, 2009, 2007) . A total of 439 BP gene sets (217 with positive enrichment; 222 with negative enrichment) were affected by CPO exposure at the 0.5 mg/kg/day dose. The 27 BP negative-enrichment gene sets that overlapped between PON1 À/À and tgHu-PON1 Q192 mice exposed to 0.5 mg/kg/day CPO included Forebrain Development (GO:0030900), Midbrain Development (GO:0030901), and Cell Death (GO:0008219), as well as the Ionotropic Glutamate Receptor Signaling Pathway (GO:0035235), Regulation of Synaptic Plasticity (GO:0048167), Synaptic Vesicle Exocytosis (GO:0016079), FIG. 6 . GSA heat maps. Heat maps of some of the particularly interesting gene sets (BP; GSA positive) that were significantly enriched (p < 0.01) between PON1 þ/þ and PON1 À/À mice exposed to 0.5 mg/kg/day CPO (A-E) or between tgHuPON1 Q192 and tgHuPON1 R192 mice exposed to 0.5 mg/kg/day CPO (F). Red color indicates increased expression. Green color indicates decreased expression.
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and Synapse Organization (GO:0050808). The Synapse Organization gene set is comprised in part by the neuroligins, AChE family members whose active sites have been modified to form trans-synaptic signaling domains. This particular gene set was significantly enriched in comparisons both among genotypes (i.e., between tgHuPON1 Q192 and tgHuPON1 R192 mice that had been exposed to 0.50 mg/kg/day CPO and between PON1 À/À and PON1 þ/þ mice that had been exposed to 0.50 mg/kg/day CPO) and also for comparisons of CPO effects within individual genotypes (i.e., when comparing CPO-exposed mice of a given genotype to vehicle-treated mice of the same genotype). Similar pathways and GO categories were identified in other studies examining the neurodevelopmental effects of CPF in neonatal rats and cultured cells (Slotkin and Seidler, 2009) , raising the likelihood that many of the effects seen in these earlier studies were due to the bioconversion of CPF to CPO by liver CYP450 enzymes. The gene expression effects almost certainly represent a mixed pattern of toxic responses, repair processes, and adaptive responses; the use of a single time point following dosing did not allow for examination of temporal effects of CPO treatment on gene expression. Additionally, there is a possibility of masking of cell-specific effects due to the complexity of cell types in the cerebellum. FIG. 7 . Synapse Organization gene set. Heat maps of the Synapse Organization gene set (BP GO_0050808) for several different comparisons. This particular gene set was significantly enriched (p < 0.01) for a number of different comparisons: tgHuPON1 R192 versus tgHuPON1 Q192 mice exposed to 0.5 mg/kg/day CPO (left); PON1 þ/þ versus PON1 À/À mice exposed to 0.5 mg/kg/day CPO (middle); tgHuPON1 Q192 mice exposed to vehicle control versus tgHuPON1 Q192 mice exposed to 0.5 mg/kg/day CPO (right). Red color indicates increased expression. Green color indicates decreased expression.
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With only two dose groups used for the microarray studies (0.35 and 0.50 mg/kg/day), it was not possible to demonstrate conclusive dose-response relationships on gene expression. Nevertheless, a number of genes did show either increasing or decreasing gene expression with increasing dose that was confirmed by qRT-PCR. These included neuroligin 2 (Nlgn2), metabotropic glutamate receptor 2 (Grm2), glutathione Stransferase a4 (Gsta4), and synapsin II (Syn2).
Second, this study showed that PON1 status was important in modulating the effects of CPO exposure, both on brain AChE inhibition and on gene expression effects in the cerebellum. PON1 À/À mice showed the most inhibition of brain AChE after exposure to CPO from PND 4 to 21, followed by tgHuPON1 Q192 mice. This is consistent with lack of plasma CPO hydrolytic activity in the PON1 À/À mice and with the lower catalytic efficiency of CPO hydrolysis by the PON1 Q192 alloform compared with the PON1 R192 alloform. As with previous studies examining acute toxicity in adult mice (Cole et al., 2005; Furlong, 2008; Jansen et al., 2009; Li et al., 2000) , the PON1 R192 alloform was more protective of CPO exposure than the PON1 Q192 alloform. Furthermore, gene expression effects analyzed by GSA were the most similar between the CPO metabolic-deficient tgHuPON1 Q192 and PON1 À/À mice compared with the tgHuPON1 R192 and PON1 þ/þ mice, which are more efficient at detoxifying CPO. Significantly enriched gene sets overlapped between the tgHuPON1 Q192 and PON1 À/À mice, but not among mice of other genotypes. Direct comparison of PON1 À/À and PON1 þ/þ mice exposed to 0.5 mg/kg CPO identified 126 BP gene sets that were significantly differentially affected between the two genotypes, including Brain Development (GO:0007420), Neurotransmitter Secretion (GO:0007269), Axon Guidance (GO:0007411), Neurite Development (GO:0031175), Cell Death (GO:0008219), Ionotropic Glutamate Receptor Signaling Pathway (GO:0035235), Response to Reactive Oxygen Species (GO:0000302), and Cation Transport (GO:0006812). Similarly, direct comparison of tgHuPON1 Q192 and tgHuPON1 R192 mice exposed to 0.5 mg/kg CPO was informative for understanding genes and pathways that were affected differently between mice expressing these two PON1 alloforms, which differ in efficiency of CPO detoxication. Figure 6 shows this difference between genotypes dramatically for the Nervous System Development (GO:0007399) BP gene set. In both the PON1 À/À versus PON1 þ/þ and tgHuPON1 Q192 versus tgHuPON1 R192 comparisons of mice treated with 0.5 mg/kg/day CPO, mitochondrial gene sets (e.g., mitochondrial respiratory chain GO:0005746 and mitochondrial intermembrane space GO:0005758) were prominent among the CC gene sets that were significantly differentially affected between genotypes. Analysis by both GSA and IPA showed that PON1 À/À mice and tgHuPON1 Q192 mice were more sensitive than PON1 þ/þ and tgHuPON1 R192 mice to the gene expression changes associated with CPO exposure.
As might be expected, there were differences in cerebellar gene expression among genotypes, even in the absence of CPO exposure. Confirming earlier studies showing PON1 expression in the brain, in the current study, PON1 was expressed in the cerebellum of PON1 þ/þ , tgHuPON1 Q192 , and tgHuPON1 R192 mice, but not PON1 À/À mice. Surprisingly, PON2 expression was also reduced in the PON1 À/À cerebellum, regardless of treatment. PON2 mRNA levels were 17-33% lower in the PON1 À/À , tgHuPON1 Q192 , and tgHuPON1 R192 mice than in the PON1 þ/þ mice. This was likely due to disruption of as-yet uncharacterized cisregulatory elements when the nearby PON1 gene was inactivated. It is possible that some of the differences in CPO-associated effects on gene expression between the PON1 þ/þ mice and mice of the other three genotypes were due to reduced expression of PON2, which is localized to mitochondria and could serve a protective role against oxidative damage.
These results indicate that both PON1 activity and the PON1 Q192R alloform are important in modulating the developmental effects of CPO exposure, even as early as PND 4, when PON1 levels are low. At PND 4, the PON1 À/À mice were~2.5-times more sensitive to brain AChE inhibition compared with PON1 þ/þ mice. It will be interesting to see if this modulation extends back into prenatal development and to determine the relative importance of maternal versus embryonic PON1 status in protecting against OP exposures. Moreira et al. (2010) showed that gestational CPF exposure (at as low as 2 mg/kg/day maternal exposure) affected genes in the fetal brain that were involved in cell division, neurotransmission, and nervous system development. Determining the extent to which these effects are modulated by maternal and fetal PON1 levels and HuPON Q192R genotype will provide valuable information for assessing the risks associated with OP exposures during pregnancy.
SUPPLEMENTARY DATA
Supplementary data are available online at http://toxsci. oxfordjournals.org/. 
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